Insulet price target lowered to $315 from $360 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Insulet (PODD) to $315 from $360 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock trades at a slight discount relative to its peer group average of high-growth profitable companies, but the firm believes that it should trade at in-line levels if not at a premium to its peer group given its higher revenue and profit growth prospects.